Kala Bio Inc.
KALA
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.1K
Close$
$0.93
387.8% upside
Current Fair Value
387.8% upsideUndervalued by 387.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14,098.00 |
|---|---|
| Enterprise Value | $-214,902.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-165.5 |
| Beta | -2.41 |
| Outstanding Shares | 74,159 |
Return
| Return on Equity | -93.53% |
|---|---|
| Return on Assets | -79.94% |
| Return on Invested Capital | -273.71% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-6.00
Average shareholder expectationRevenue Estimate
$25.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-6.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 945.54%▲ 924.69% |
|---|---|
| Total Invested | $1.21M▲ 312.71% |
| Investors Holding | 14▼ 12.00% |
ESG Score
No data
About Kala Pharmaceuticals Inc
6 employees
CEO: Mark Iwicki Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus ba...